Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Clinical Pharmacology and Therapeutics
|
September 9, 2024
Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-Analysis
John Maringwa, Paul Matthias Diderichsen, Chandni Valiathan
Toxicology
|
July 25, 2007
Changes in expression of fibrotic markers and histopathological alterations in kidneys of mice chronically exposed to low and high Cd doses
Sandy Thijssen, Ivo Lambrichts, John Maringwa, et al.
Toxicology
|
November 23, 2006
Chronic exposure of mice to environmentally relevant, low doses of cadmium leads to early renal damage, not predicted by blood or urine cadmium levels
Sandy Thijssen, John Maringwa, Christel Faes, et al.
Journal of Clinical Pharmacology
|
October 4, 2014
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
John Maringwa, Matts Kågedal, Ulrika Wählby Hamrén, et al.
Toxicology
|
May 15, 2007
Low cadmium exposure triggers a biphasic oxidative stress response in mice kidneys
Sandy Thijssen, Ann Cuypers, John Maringwa, et al.
Clinical Pharmacology and Therapeutics
|
December 6, 2020
Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure
John Maringwa, Maria Luisa Sardu, Yaming Hang, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 20, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
Thao-Nguyen Pham, Anna Largajolli, Maria Luisa Sardu, et al.
British Journal of Clinical Pharmacology
|
December 24, 2016
Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer
Kathryn Brown, Craig Comisar, Han Witjes, et al.
Journal of Comparative Effectiveness Research
|
August 12, 2025
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma
Jianming He, Karen Chiang, Xiwu Lin, et al.
Clinical and Translational Science
|
January 18, 2022
Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC
Neeraj Gupta, Karen L Reckamp, David R Camidge, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Clinical Pharmacology and Therapeutics
|
September 9, 2024
Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-Analysis
John Maringwa, Paul Matthias Diderichsen, Chandni Valiathan
Toxicology
|
July 25, 2007
Changes in expression of fibrotic markers and histopathological alterations in kidneys of mice chronically exposed to low and high Cd doses
Sandy Thijssen, Ivo Lambrichts, John Maringwa, et al.
Toxicology
|
November 23, 2006
Chronic exposure of mice to environmentally relevant, low doses of cadmium leads to early renal damage, not predicted by blood or urine cadmium levels
Sandy Thijssen, John Maringwa, Christel Faes, et al.
Journal of Clinical Pharmacology
|
October 4, 2014
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
John Maringwa, Matts Kågedal, Ulrika Wählby Hamrén, et al.
Toxicology
|
May 15, 2007
Low cadmium exposure triggers a biphasic oxidative stress response in mice kidneys
Sandy Thijssen, Ann Cuypers, John Maringwa, et al.
Clinical Pharmacology and Therapeutics
|
December 6, 2020
Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure
John Maringwa, Maria Luisa Sardu, Yaming Hang, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 20, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
Thao-Nguyen Pham, Anna Largajolli, Maria Luisa Sardu, et al.
British Journal of Clinical Pharmacology
|
December 24, 2016
Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer
Kathryn Brown, Craig Comisar, Han Witjes, et al.
Journal of Comparative Effectiveness Research
|
August 12, 2025
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma
Jianming He, Karen Chiang, Xiwu Lin, et al.
Clinical and Translational Science
|
January 18, 2022
Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC
Neeraj Gupta, Karen L Reckamp, David R Camidge, et al.
Page
of 2